Proteasome inhibition by bortezomib parallels a reduction in head and neck cancer cells growth, and an increase in tumor-infiltrating immune cells

Head and neck cancer (HNC) has frequently an aggressive course for the development of resistance to standard chemotherapy. Thus, the use of innovative therapeutic drugs is being assessed. Bortezomib is a proteasome inhibitor with anticancer effects. In vitro antitumoral activity of Bortezomib was in...

Descripción completa

Detalles Bibliográficos
Autores principales: Benvenuto, Monica, Ciuffa, Sara, Focaccetti, Chiara, Sbardella, Diego, Fazi, Sara, Scimeca, Manuel, Tundo, Grazia Raffaella, Barillari, Giovanni, Segni, Maria, Bonanno, Elena, Manzari, Vittorio, Modesti, Andrea, Masuelli, Laura, Coletta, Massimo, Bei, Roberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8463577/
https://www.ncbi.nlm.nih.gov/pubmed/34561494
http://dx.doi.org/10.1038/s41598-021-98450-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8463577/
https://www.ncbi.nlm.nih.gov/pubmed/34561494
http://dx.doi.org/10.1038/s41598-021-98450-6

Ejemplares similares